Viking Therapeutics Inc. (VKTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Viking Therapeutics Inc. (VKTX) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How VKTX Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.00B | 0% | -9.8% | -$359.6M | -$278.7M | -45% |
| FY 2024 | $4.00B | 0% | -3.8% | -$110.0M | -$87.8M | -13.8% |
| FY 2023 | $4.00B | 0% | -2.5% | -$85.9M | -$73.4M | -7.1% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring VKTX)
- ✓Live walkthrough of VKTX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
VKTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VKTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VKTX. Explore sector supply chains on /butterfly.
VKTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Viking Therapeutics Inc. (VKTX)?
In FY 2025 (10-K), VKTX converted $4.0B of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).